Home > Suppliers > Dianova GmbH >

Anti-IDH1 R132H Monoclonal Antibody

Anti-IDH1 R132H Monoclonal Antibody

Alternative Views:

Our Price: $649.00

Product Code: DIA-H09

500 µl

Product Details
Product Code DIA-H09
Product: Anti-IDH1 R132H Monoclonal Antibody
Description: Anti-IDH1 R132H / DIA-H09 Mouse monoclonal anti-brain tumor marker (Astrocytoma, Oligodendroglioma)
Category: Monoclonal Antibody
Species: Mouse
Clone: H09
Immunogen: Synthetic peptide, amino acid sequence CKPIIIGHHAYGD
Isotype: Mouse IgG2a
Species Reactivity: Human
Form: Lyophilized, in PBS with 2% BSA, 0.05% NaN3, pH 7.4. Antibody purified from culture supernatant.
Reactivity: Antibody clone H09 reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor specimens. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. The high frequency and distribution of the IDH1 R132H mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma WHO grade II from pilocytic astrocytoma or ependymoma. Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis. This antibody is highly useful for tumor classification and in detecting single infiltrating tumor cells.
Applications: Immunohistochemistry (IHC); Immunohistochemistry (Paraffin-embedded Sections); Western Blot
Working Dilutions: WB 1:500
IHC 1:20
Concentration: 0.2 mg/ml
Positive Control: Oligodendroglioma, diffuse astrocytoma
Negative Control: Pilocytic astrocytoma, primary glioblasto-ma (ca. 95% of cases negative)
Storage: 2-8°C. For long term storage aliquot and freeze at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Images: A: Strong reaction of IDH1 mutation specific antibody clone H09 in tumor center of anaplastic oligoastrocytoma.
B: Infiltration zone of anaplastic astrocytoma with specific labelling of infiltrating glioma cells by antibody clone H09.
C: Identification of single tumor cells in white matter distant from tumor center with antibody clone H09.
D: Cortex infiltrated by oligodendroglioma with specific labelling of tumor cells by antibody clone H09.
E: Double staining of GFAP (glial fibrillary acidic protein, red) and clone H09 (brown) of oligodendroglioma infiltration zone demonstrating specific labelling of tumor cells but not of GFAP positive reactive astrocytes.
F: Strong reaction of antibody clone H09 with IDH1 R132H mutated diffuse astrocytoma (left) but not with wild type tumor (right).

(pictures courtesy of Prof. Dr. med. Andreas von Deimling, Department of Neuropathology, University Heidelberg/ Clinical Co-operation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany)
References: 1. Capper D et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118(5): 599-601, 2009
2. Capper D et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20(1): 245-254, 2010
3. Preusser M et al. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clinical Neuropathology, 30(5):217-230, 2011
4. Van den Bent MJ et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol 112:173–178, 2013
5. Schumacher T et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, DOI:10.1038/nature13387
6. David NL et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol., 131:803-820, 2016
This product is sold for laboratory research use or further manufacturing only and should not be used for human therapeutic or diagnostic applications. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process.

Share your knowledge of this product. Be the first to write a review »